Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ektomun
- Development stage
- Preclinical
- Lead developer
- Lindis Biotech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ektomun is a bispecific trifunctional antibody (trAb) that targets both GD2, a tumor-associated antigen highly expressed in neuroblastoma and other neuroectodermal tumors, and CD3 on T cells. It is designed to recruit and activate T cells at the tumor site while also engaging accessory immune cells via its Fc region. This trifunctional mechanism enables direct cytotoxicity against GD2-expressing tumor cells through T cell activation, proinflammatory cytokine release, and antibody-dependent cellular cytotoxicity (ADCC). Preclinical studies have demonstrated that Ektomun induces strong antitumor responses in models of neuroblastoma by activating effector immune cells and mediating GD2-dependent cytotoxic effects. The drug was initially developed by Lindis Biotech using their Triomab platform[1][2][3][4][7].
- Brand names
- Ektomab
02
Targets
GD2FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on Ektomun.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ektomun.